Differential expression of protease-activated receptors 1, 2, and 4 on human endothelial cells from different vascular sites

Pathobiology. 2004;71(1):52-8. doi: 10.1159/000072962.

Abstract

Objective: Protease-activated receptors (PARs) mediate DNA synthesis in endothelial cells when activated by serine proteases. However, despite the existence of heterogeneity among endothelial cells from each tissue, the responses to PAR-1, PAR-2, and PAR-4 activation are poorly defined and compared between endothelial cells from different sites. The aim of this study was to investigate whether PAR-mediated DNA synthesis differed in various endothelial cell types.

Methods: We examined the incorporation of BrdU by human pulmonary artery endothelial cells (HPAECs), human aortic endothelial cells (HAECs), and human umbilical vein endothelial cells (HUVECs).

Results: When the endothelial cells were treated with the selective PAR-1-activating peptide, SFLLRN, HAECs showed the highest BrdU incorporation rate (182 +/- 28%). In contrast, treatment with the PAR-2-activating peptide, SLIGKV, resulted in the highest BrdU incorporation rate (173 +/- 37%) in HPAECs, when pretreated with TNF-alpha. The PAR-4-activating peptide, GYPGQV, induced DNA synthesis in HPAECs and HAECs, but not in HUVECs.

Conclusion: These findings suggest that each PAR preferentially targets an endothelial cell type, and thus plays a distinct role in diverse physiological or pathological conditions.

Publication types

  • Comparative Study

MeSH terms

  • Aorta / cytology
  • Aorta / drug effects
  • Aorta / metabolism
  • Cell Division / drug effects
  • Cells, Cultured
  • Endothelium, Vascular / cytology*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism*
  • Humans
  • Oligopeptides / pharmacology
  • Pulmonary Artery / cytology
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / metabolism
  • RNA, Messenger / analysis
  • Receptor, PAR-1 / biosynthesis*
  • Receptor, PAR-1 / drug effects
  • Receptor, PAR-2 / biosynthesis*
  • Receptor, PAR-2 / drug effects
  • Receptors, Thrombin / biosynthesis*
  • Receptors, Thrombin / drug effects
  • Reverse Transcriptase Polymerase Chain Reaction
  • Thrombin / pharmacology
  • Umbilical Veins / cytology
  • Umbilical Veins / drug effects
  • Umbilical Veins / metabolism

Substances

  • Oligopeptides
  • RNA, Messenger
  • Receptor, PAR-1
  • Receptor, PAR-2
  • Receptors, Thrombin
  • seryl-leucyl-isoleucyl--glycyl-lysyl-valine
  • Thrombin
  • protease-activated receptor 4